MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

4.750 -0.060 (-1.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Unicycive Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500... 
Via Benzinga
Why Unicycive Therapeutics Stock Is Exploding Higher Monday
Unicycive Therapeutics Inc (NASDAQ: UNCY) shares are exploding higher Monday after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver... 
Via Benzinga
Unicycive: The Company Developing Key Kidney Therapies
by\nJohnny Rice, Benzinga Contributor 
Via News Direct
Unicycive: The Company Developing Key Kidney Therapies
Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. 
Via TheNewswire.com
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
 
Via Benzinga
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
By Julian Richard, Benzinga 
Via TheNewswire.com
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers 
Via News Direct
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and... 
Via Benzinga
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive: The Company Developing Key Kidney Therapies
Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Unicycive: This Biotech Company Receives Promising Results From New Trial
Unicycive: This Biotech Company Receives Promising Results From New Trial 
Via News Direct
Unicycive: This Biotech Company Receives Promising Results From New Trial
Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the... 
Via Benzinga
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
Via Benzinga
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the... 
Via Benzinga
Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday. 
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story